-80℃ for 6 months, avoid repeated freeze-thaw cycles.
Deliverables
1. Delivery of 3 ml of lentivirus containing three sgRNAs, with a viral titer greater than 1 × 10^7 TU/ml, and 125 µl of polybrene at 8 µg/µl.
2. A report will be provided, including the sgRNA sequences, a schematic diagram of the lentiviral construct, and resistance information.
3. Genomic amplification primers for the target gene.
CRISPR lentivirus Three in One Explanation
Product Advantages
1. Lower cost: The “three-in-one” product features a more streamlined manufacturing process, reducing production costs for companies and enabling them to replace the experimental time and funding previously required by researchers.
2. Higher quality: Gene knockout is more stable, making it easier to obtain “monoclonal, homozygous” knockout cell lines.
3. Faster turnaround: Our ready‑to‑use products have already undergone pre‑validation of target sgRNAs.
Product Application
1. Functional deficiency studies: Systematically elucidating the essential roles of genes in physiological and pathological processes.
2. Disease model construction: Generating complete gene‑knockout phenotypes that mimic genetic disorders, cancers, or immunodeficiencies.
3. Drug target validation: Using gene knockout approaches to assess the functional dependency and therapeutic potential of candidate targets.
4. Transgenic animal development: Generating gene‑knockout mice and other model organisms.
5. Exploration of drug resistance mechanisms: Identifying key genes associated with drug sensitivity.
